Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

22/07/24	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
09/12/21	TearLab Corporation Announces Board Appointments	CI
09/12/21	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	CI
09/11/21	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	CI
16/09/21	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	CI
28/07/20	TearLab Appoints Adam Szaronos as Chief Commercial Officer	CI
08/07/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	CI
08/07/20	TearLab Corporation to Seek Acquisitions	CI
26/06/20	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
11/05/20	TearLab Corporation Announces Board Appointments	CI
11/05/20	Tearlab Mulls Inorganic Growth Opportunities	CI
10/05/20	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	CI
10/05/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	CI

09/07/20	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
26/06/20	TearLab: 1Q Earnings Snapshot	AQ
26/06/20	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
08/06/20	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	AQ
29/05/20	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	AQ

Manager	Title	Age	Since
Adam Szaronos CEO	Chief Executive Officer	-	31/03/2026
Benjamin D. Sullivan CTO	Chief Tech/Sci/R&D Officer	-	16/07/2009
John Lund DFI	Director of Finance/CFO	60	30/06/2022

Director	Title	Age	Since
Uri Geiger BRD	Director/Board Member	58	08/07/2020
James V. Mazzo CHM	Chairman	68	08/12/2021
Richard Lindstrom BRD	Director/Board Member	78	31/08/2004

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/07/20	Joseph S. Jensen	Tender	Chief Executive Officer	29,206	0.1196%
09/07/20	Michael Marquez	Tender	Chief Financial Officer	500	0.0020%
09/07/20	Paul M. Karpecki	Tender	Director	102,200	0.4187%

TearLab Corporation Share Price

Stocks

Medical Equipment, Supplies & Distribution

Latest news : TearLab Corporation

Press Releases: TearLab Corporation

Managers and Directors: TearLab Corporation

Latest insider transactions

Glasses, Spectacles & Contact Lenses

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TEARLAB CORPORATION	-.--%	+2.84%	-	-	1.41M
ESSILORLUXOTTICA	+2.57%	-4.57%	-38.80%	-5.53%	87.21B
ALCON INC.	+2.48%	-1.18%	-15.63%	-16.50%	35.89B
THE COOPER COMPANIES, INC.	+0.88%	-1.38%	+3.03%	-17.87%	14.78B
LENSKART SOLUTIONS LIMITED	+1.79%	+8.95%	-	-	11.4B
SHANGHAI CONANT OPTICAL CO., LTD.	-3.94%	+4.44%	-7.22%	+687.50%	2.51B
AUTEK CHINA INC.	-1.92%	-4.50%	-41.45%	-58.30%	1.49B
MENICON CO., LTD.	-3.24%	-2.85%	+51.87%	-6.76%	918M
MINGYUE OPTICAL LENS CO.,LTD.	+0.44%	-0.93%	-38.99%	-20.28%	883M
PEGAVISION CORPORATION	-0.55%	-4.37%	+13.86%	+6.32%	869M
Average	-0.16%	-0.33%	-9.17%	+71.07%	17.33B
Weighted average by Cap.	+2.11%	-2.11%	-27.36%	+1.94%